J Kalita1, A K Kohat2, U K Misra2, S K Bhoi2. 1. Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. Electronic address: jayanteek@yahoo.com. 2. Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
Abstract
BACKGROUND: There is no head on comparison of amitriptyline (AMT) and pregabalin (PG) in relieving pain and disability in chronic low backache (CLBA). This randomized controlled trial reports the efficacy and safety of AMT and PG in CLBA. METHODS:Patients with CLBA, 15-65 years of age without specific cause and significant neurological deficit were included. Severity of pain was assessed by Visual Analogue Scale (VAS) and disability by Oswestry Disability Index (ODI). Patients were followed up at 6 and 14 weeks and their VAS score, ODI and side effect were noted. Primary outcome was pain relief (>50% improvement in VAS score) at 14 weeks and secondary outcome were reduction in ODI (>20%) and side effects. RESULTS:200 patients with CLBA were randomized to AMT (n=103) and PG (n=97) using random numbers. The VAS score and ODI improved significantly following AMT and PG at 6 and 14 weeks compared to baseline. The improvement in pain (57.3% Vs 39.2%; P=0.01) and disability (65% Vs 49.5%; P=0.03) however was more in AMT group. The composite side effects were similar in both groups. CONCLUSION:AMT and PG are effective in CLBA but AMT reduced pain and disability significantly compared to PG.
RCT Entities:
BACKGROUND: There is no head on comparison of amitriptyline (AMT) and pregabalin (PG) in relieving pain and disability in chronic low backache (CLBA). This randomized controlled trial reports the efficacy and safety of AMT and PG in CLBA. METHODS:Patients with CLBA, 15-65 years of age without specific cause and significant neurological deficit were included. Severity of pain was assessed by Visual Analogue Scale (VAS) and disability by Oswestry Disability Index (ODI). Patients were followed up at 6 and 14 weeks and their VAS score, ODI and side effect were noted. Primary outcome was pain relief (>50% improvement in VAS score) at 14 weeks and secondary outcome were reduction in ODI (>20%) and side effects. RESULTS: 200 patients with CLBA were randomized to AMT (n=103) and PG (n=97) using random numbers. The VAS score and ODI improved significantly following AMT and PG at 6 and 14 weeks compared to baseline. The improvement in pain (57.3% Vs 39.2%; P=0.01) and disability (65% Vs 49.5%; P=0.03) however was more in AMT group. The composite side effects were similar in both groups. CONCLUSION: AMT and PG are effective in CLBA but AMT reduced pain and disability significantly compared to PG.
Authors: Tess E Cooper; Lauren C Heathcote; Jacqui Clinch; Jeffrey I Gold; Richard Howard; Susan M Lord; Neil Schechter; Chantal Wood; Philip J Wiffen Journal: Cochrane Database Syst Rev Date: 2017-08-05
Authors: Marta Imamura; Satiko Tomikawa Imamura; Rosa Alves Targino; León Morales-Quezada; Luis C Onoda Tomikawa; Luis G Onoda Tomikawa; Fabio M Alfieri; Thais R Filippo; Ivan D da Rocha; Raul Bolliger Neto; Felipe Fregni; Linamara Rizzo Battistella Journal: J Pain Date: 2016-01-30 Impact factor: 5.820
Authors: Jürg Schliessbach; Andreas Siegenthaler; Lukas Bütikofer; Andreas Limacher; Peter Juni; Pascal H Vuilleumier; Ulrike Stamer; Lars Arendt-Nielsen; Michele Curatolo Journal: PLoS One Date: 2018-05-09 Impact factor: 3.240
Authors: Carina Riediger; Tibor Schuster; Kristian Barlinn; Sarah Maier; Jürgen Weitz; Timo Siepmann Journal: Front Neurol Date: 2017-07-14 Impact factor: 4.003